HL 301
Alternative Names: HL301Latest Information Update: 04 Jun 2024
Price :
$50 *
At a glance
- Originator Hanlim Pharmaceutical
- Developer Hanlim Pharmaceutical; HL Genomics
- Class Antibronchitics; Herbal medicines; Traditional Chinese medicine
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Bronchitis
- Phase II Chronic obstructive pulmonary disease
Most Recent Events
- 01 Jun 2023 Phase-II clinical trials in Chronic obstructive pulmonary disease in South Korea (PO) (NCT06434792)
- 06 Apr 2021 No development reported - Phase-III for Bronchitis in South Korea (PO)
- 17 Nov 2020 Hanlim Pharmaceutical plans a phase II trial for Radiation injuries in South Korea in November 2020 (PO) (NCT04632342)